最新临床试验：非高危神经母细胞瘤年轻患者的反应及生物学危险因素导向治疗

这是经美国国家癌症研究所批准的一项多中心随机对照 III期临床试验，目的是研究治疗非高危神经母细胞瘤年轻患者的反应与基于生物学的危险因素引导的疗效。有时肿瘤在发展前可能不需要治疗。在这种情况下，观察可能就足够了。测量肿瘤细胞中的生物标志物有助于计划何时需要有效的治疗以及什么是最好的治疗。基于反应和生物学的危险因素引导治疗对非高危神经母细胞瘤患者可能有效，并有助于避免标准治疗的一些风险和副作用。

该临床试验在全美181家医院进行开展。

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.

Trial IDs

Status: Active
Age: 17 months and under
Gender: Male or Female
Location: 181 locations